YR
Therapeutic Areas
Glenmark Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GRC 54276 | Asthma/COPD | Phase 2 |
| GRC 27864 | Atopic Dermatitis | Phase 2 |
| GBR 830 | Oncology | Phase 1 |
| Ryaltris (GSP 301) | Allergic Rhinitis | Approved |
| Bevacizumab Biosimilar | Oncology | Approved |
| Adalimumab Biosimilar | Autoimmune Disorders | Phase 3 |
Leadership Team at Glenmark Pharmaceuticals
GS
Glenn Saldanha
Chairman & Managing Director
CP
Cherylann Pinto
Executive Director & Chief Financial Officer
RC
Robert Crockart
Chief Commercial Officer - Europe
AM
Alok Malik
President - India Formulations
DM
Dr. Monika Tandon
Senior Vice President - Clinical Development